Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Radiotherapy 10Magnetic Resonance Spectroscopy 7Early Intervention, Educational 7Standard of Care 6Interviews as Topic 6Educational Status 6Radiotherapy, Conformal 5Practice Guidelines as Topic 5Methods 5Cyclophosphamide 5Vincristine 4Specimen Handling 4Psychiatric Rehabilitation 4Cisplatin 4Brachytherapy 4Biopsy 4Surgical Procedures, Operative 3Radiosurgery 3Granulocyte Colony-Stimulating Factor 3Fluorodeoxyglucose F18 3Filgrastim 3Etoposide 3Dexamethasone 3Counseling 3Carboplatin 3pegaspargase 2motexafin gadolinium 2etoposide phosphate 2X-Rays 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × NETWORK × oregovomab × Clear all
NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

GOG Foundation

Phase NA Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡